ID
23417
Beschrijving
Clinical Study ID: 100450 Study Title: Comparative study of the immunogenicity and protective efficacy of GlaxoSmithKline Biologicals’ rec-DNA hepatitis B vaccine with or without hepatitis B immunoglobulins (HBIg) in newborns of HBeAg+ mothers. Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00240526 https://clinicaltrials.gov/ct2/show/NCT00240526 Sponsor: GlaxoSmithKline Collaborators: N/A Phase: phase 4 Study Recruitment Status: Completed Generic Name: Hepatitis B Vaccine, Recombinant Trade Name: Engerix-B Study Indication: Hepatitis B Documentation part: Visit 24, Year 18, Long Term Follow-Up, 18 Years +/- 6 Months
Link
https://clinicaltrials.gov/ct2/show/NCT00240526
Trefwoorden
Versies (1)
- 04-07-17 04-07-17 -
Geüploaded op
4 juli 2017
DOI
Voor een aanvraag inloggen.
Licentie
Creative Commons BY-NC 3.0
Model Commentaren :
Hier kunt u commentaar leveren op het model. U kunt de tekstballonnen bij de itemgroepen en items gebruiken om er specifiek commentaar op te geven.
Itemgroep Commentaren voor :
Item Commentaren voor :
U moet ingelogd zijn om formulieren te downloaden. AUB inloggen of schrijf u gratis in.
Rec-DNA hepatitis B vaccine with or without hepatitis B immunoglobulins Visit 24 NCT00240526
Visit 24 Rec-DNA hepatitis B vaccine with or without hepatitis B immunoglobulins NCT00240526
Similar models
Visit 24 Rec-DNA hepatitis B vaccine with or without hepatitis B immunoglobulins NCT00240526
C0005834 (UMLS CUI-2)
C0474232 (UMLS CUI-3)
C0011008 (UMLS CUI [1,2])
C0011008 (UMLS CUI [1,2])
C1457887 (UMLS CUI [1,2])
C0267797 (UMLS CUI [2])
C1457887 (UMLS CUI [1,2])
C0267797 (UMLS CUI [2])